Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Merck sees Oxytrol OTC as cushion against Rx patent expirations; Pfizer acquisitions boost consumer sales 16% in Q4; Latin America stands out for Mead Johnson.
You may also be interested in...
Mead Johnson Hopes To Milk JV For Latin American Growth
An 80-20 joint venture with dairy producer SanCor likely will help Mead Johnson cement its footprint in Argentina and other Latin American countries. Meanwhile, the pediatric nutritionals firm maintains muted expectations for the U.S. in 2012.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.